• Shaking the Myth of Real-World Evidence: Updates From the RWE Transparency Initiative

    ISPOR is leading efforts in the area of RWE transparency in collaboration with ISPE, Duke Margolis and NPC. This session will provide updates from the initiative including progress on the study registration site and the special task force on RWE protocol templates.

  • The 4th Industrial Revolution, Digital Transformation and Patient Centricity: A Leadership View

    In this presentation we will explore what the 4th Industrial Revolution is, how it impacts on the progressive movement towards digital transformation in our workplace. We will show that there is an inevitable convergence between the health ecosystem and the digital world.

  • Elements of Pharmaceutical/Biotech Pricing

    This course is designed for individuals with intermediate experience within a single healthcare system wishing to broaden their appreciation of other reimbursement systems.

  • CHEERS II: Bold Directions for New Reporting Standards?

    This webinar will discuss the rationale for the revision of the original Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guidelines and outline directions for the new reporting standards, as suggested by a Delphi survey.

  • The Proper Order of Things is Often A Mystery: A Novel Approach to Selecting Treatment Sequences

    In this webinar, we will consider the apparent disconnect between HTA assessments of treatments within a specified location in a treatment sequence and clinical practice where a treatment sequence is tailored to the patient. Following an overview of the standard approach to HTA assessment of treatments in a sequence, we will present a novel approach to modelling treatment sequences which replicates the clinicians decision-making process. The approach will be illustrated using the example of relapsing remitting MS. Finally, we will provide attendees with examples of the information that can potentially be generated by the model to inform decision-making about treatment sequencing.

  • Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

    This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

  • Reimbursement Systems for Pharmaceuticals in Europe

    This course is designed for individuals with intermediate experience within a single healthcare system wishing to broaden their appreciation of other reimbursement systems.

  • Using Patient Preferences to Inform Decision Making

    There is currently a major gap in guidance and patient preference literature on how decision makers can use patient preferences and how researchers can conduct fit-for-purpose studies that are more relevant to decision makers. The current regulatory and assessor landscape will be discussed including the European Union’s Innovative Medicines Initiative (IMI) and the Medical Device Innovation Consortium (MDIC). The task force is presenting their work to date with the request for feedback.

  • Virtual ISPOR Europe 2020

    With new, on demand-only content released leading up to the conference, and a 4-day live conference schedule tailored to global audience, Virtual ISPOR Europe 2020 will be your best opportunity to interact with your peers in the HEOR community.

  • Using VA/HTA in Pursuing Innovation and Access in a Pandemic

    This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness. Where have our usual VA/HTA approaches worked and where have they proven inadequate to the challenges presented by COVID-19? Based on our learnings throughout the series, what are the emerging needs for methods, scientific research, public health, and defining and building consensus? What are the most immediate priorities for supporting innovation and access at both US and international levels? Does value-based pricing apply in the pandemic context? How do we coordinate public and private investment in these interventions and treatments?

  • Value Assessment in Alzheimer's Disease: A Focus on Equity

    An increasing number of innovative potential treatments for Alzheimer’s disease are advancing in the clinical pipeline. However, the value frameworks and health technology assessments of today may create challenges that inhibit sustainable patient access. Among those who may be hardest hit are older adults, women, and racial and ethnic minorities. However, there may be opportunities to improve the situation by modifying value frameworks to incorporate issues of equity and inclusion. Doing so will help to build a more ethical ecosystem and help to ensure greater access to innovation for those who might otherwise face barriers. This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.

  • Budget Impact Analysis I: A 6-Step Approach

    This course will describe the methods used to estimate the budget impact of a new healthcare technology and will present 6 basic steps for estimating budget impact: (1) estimating the target population; (2) selecting a time horizon; (3) identifying current and projected treatment mix; (4) estimating current and future drug costs; (5) estimating change in disease-related costs; and (6) estimating and presenting changes in annual budget impact and health outcomes. Both static and dynamic methods for estimating the budget and health impact of adding a new drug to a health plan formulary will be presented. These six steps will be illustrated using actual budget impact models. This course is designed for those with some experience with pharmacoeconomic analysis.

  • ISPOR Dubai 2020

    , Dubai | United Arab Emirates

  • Virtual ISPOR-FDA Summit 2020

  • Webinar: French Administrative Health Care Database (SNDS): Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

    Certara’s extensive experience with the recently accessible French administrative healthcare database (SNDS) has provided key insights into how the database can be used for a larger impact on patient access, health technology and public health assessments.

  • Webinar: Balancing Economics and Ethics: How Can VA/HTA Support Equitable Resource Allocation?

    Evolving data from COVID-19 tell the story we already know: the impact of this disease affects people – especially people of color - disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as in discerning how to apply such findings, how must we address questions of ethics and equity?

  • Virtual ISPOR Asia Pacific 2020

  • Virtual ISPOR 2020

  • HEOR in the Era of COVID-19-ON DEMAND

    <p>Virtual ISPOR 2020 Preconference Plenary Session<br/>Emerging in late December 2019, an infectious disease caused by a newly discovered coronavirus impacted the world. The World Health Organization declared COVID-19 as a public health emergency of international concern on January 30, 2020 and officially characterized it as a pandemic on March 11, 2020. To mitigate the impact of this new pandemic and the potential social and economic consequences that many countries around the world would face, diverse public health measures were implemented and difficult health care decisions have been taken. At the present time, there are no clearly determined vaccines or treatments for COVID-19, though many clinical trials are in progress, and the future course of this pandemic is uncertain. As the effects of this new virus unfold, there will be more data to be discussed and new questions to be asked. ISPOR 2020 Virtual will be launched on Thursday, May 14, 2020 with an online session on COVID-19 discussing health economics and outcomes research (HEOR) insights and perspectives on the evolving pandemic situation and the implications for short-term and long-term healthcare decisions.</p> <a class="button primary" href="https://www.ispor.org/conferences-education/education-training/webinars/webinar/heor-in-the-era-of-covid-19">Watch Here</a>

  • Top 10 Trends in Health Economics and Outcomes Research 2020

    <p>As the year 2020 comes into focus, many issues of interest to HEOR professionals continue to dominate the headlines. ISPOR—the professional society for health economics and outcomes research (HEOR), announced the publication of its 2020 Top 10 HEOR Trends report early this year. In the report, the Society has identified the top 10 HEOR trends that will shape the field and influence healthcare over 2020 and the near future. This 2020 Top 10 HEOR trends webinar will feature ISPOR’s Chief Science Officer, Richard J. Willke, PhD, and Associate Chief Science Officer, Lucinda Orsini, DPM, MPH, discussing the top trends for 2020 and the implications for healthcare in 2020 and beyond.</p><a class="button primary" href="https://www.ispor.org/conferences-education/education-training/webinars/webinar/top-10-trends-in-health-economics-and-outcomes-research-2020">Watch Here</a>

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×